

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number  
**WO 01/43739 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/341**,  
31/121, 7/16, 7/32, 7/06, A61P 31/04, A61L 12/10, C11D  
9/50

Goorawahl Avenue, La Perouse, New South Wales 2036  
(AU).

(21) International Application Number: PCT/AU00/01553

(74) Agent: **F B RICE & CO**; 139 Rathdowne Street, Carlton,  
Victoria 3053 (AU).

(22) International Filing Date:  
18 December 2000 (18.12.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PQ 4755 17 December 1999 (17.12.1999) AU

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**UNISEARCH LIMITED** [AU/AU]; Rupert Myers  
Building, Level 2, Gate 14 Barker Street, UNSW, Sydney,  
New South Wales 2052 (AU).

**Published:**

— *With international search report.*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ENGLAND, Dacre**  
[AU/AU]; 1/64 Belmore Road, Randwick, New South  
Wales 2031 (AU). **KJELLEBERG, Staffan** [SE/AU]; 22

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: INHIBITION OF TWO-COMPONENT SIGNAL TRANSDUCTION SYSTEMS

(57) Abstract: The present invention provides compositions and methods for inhibition activities and actions of microorganisms, particularly bacteria. The compositions and methods are based primarily on the inhibition of two-component signal transduction systems with holo-genated furanones and related 3-haloalkenones.

WO 01/43739 A1

*Inhibition of Two-Component Signal Transduction Systems*

FIELD OF THE INVENTION

5           The present invention is directed generally to compositions and methods for inhibition of activities and actions of microorganisms, particularly inhibition of two-component signal transduction systems.

BACKGROUND OF THE INVENTION

10           Two-component signal transduction systems play important roles in the growth and maintenance and functionality of many different microorganisms. Examples include, but not are limited to, regulation of the production of exopolysaccharides and virulence factors; the regulation of motility, swarming, attachment and biofilm formation; and growth and  
15 maintenance of viability.

          There have been a limited number of reports of inhibitors of two-component signal transduction systems. Roychoudhury and co-workers (1993) screened a large bank of compounds in an assay that determined the activity of the AlgR2/AlgR1 system in *Pseudomonas aeruginosa* by measuring  
20 the transcription of a plasmid borne *algD-xylE* fusion. The AlgR2/AlgR1 two-component system plays a role in regulating the production of the exopolysaccharide alginate (Deretic *et al.*, 1989). Of the 25,000 compounds screened, two classes were identified that significantly inhibited transcription of the *algD-xylE* fusion. Among these were Inhibitor A,  
25 belonging to a class of isothiazalones, and Inhibitor B, a member of the quaternary imidazoles. Inhibitor A was shown to inhibit the autophosphorylation of the histidine protein kinase (HPK) AlgR2. Inhibitor B — interfered with the binding of the response regulator (RR) AlgR1, in its phosphorylated form, to its target DNA promoter site, as determined in a gel  
30 mobility shift assay. The authors did not indicate whether the compounds reduced *in vivo* alginate production or had any antibacterial activity. More recently, Ulijasz and Weisblum (1999) carried out further *in vitro* experiments with Inhibitor A and the VanS/VanR system which controls inducible vancomycin resistance in *Enterococcus faecium* (Arthur *et al.*,  
35 1992). This study demonstrated that inhibitor A inhibits the phosphoryl transfer from the phosphorylated form of the VanS HPK to its coupled

response regulator VanR *in vitro*. The authors concluded that inhibitor A was acting on the response regulator VanR in such a way that it blocked phosphoryl transfer from VanS to VanR. This finding conflicts with those of Roychoudhury *et al.*, (1993), where inhibitor A was shown to inhibit autophosphorylation of the HPK AlgR2.

Domagala *et al.* (1998) have identified another class of inhibitors of two-component signal transduction systems. This group screened for compounds that could de-phosphorylate the soluble HPK NRII *in vitro*, and identified a number of diphenolic methanes which showed significant activity. The compounds were also tested against two-component systems *in vivo* using *Escherichia coli* and were demonstrated to be active. The assays used were of the authors' devising and were not described in great detail.

Those diphenolic methanes that appeared most active against two-component signal transduction systems were tested for antibacterial activity and inhibited the growth of a number of Gram positive organisms, including *Bacillus subtilis*, *Staphylococcus aureus*, *Enterococcus faecium* and *Streptococcus pyogenes*. Interestingly, drug resistant strains of both *E. faecium* and *S. aureus* remained sensitive. The Gram negative bacterium *E. coli* was not sensitive but a cell wall permeable (*imp* minus) strain, *E. coli* LKY, had sensitivity approaching that of the various Gram positive organisms. The compounds were also found to have a second mode of action, that of membrane perturbation, which was determined using propidium iodide uptake experiments.

Barrett *et al.* (1998) showed that a family of hydrophobic tyramines could interfere with the normal function of two-component signal transduction systems. The most potent of these compounds, was designated RWJ-49815. The authors demonstrated that this family of compounds inhibited the autophosphorylation of the purified HPK KinA of *B. subtilis*, and also showed that these compounds interfered with the normal activity of the *in vivo* Taz/OmpR two-component assay of Jin and Inouye (1993) described below.

RWJ-49815 and its analogues also proved to be potent Gram positive antibacterial compounds, active at concentrations of 1-2 µg/ml against *S. aureus*, *E. faecium* and *Streptococcus pneumoniae*.

A second paper published by members of the same laboratory identified a further class of inhibitors of two-component systems, the

substituted salicylanilides (MacLiel *et al.*, 1998). *In vitro* tests using KinA and its RR partner SpoOF showed that these compounds inhibited the autophosphorylation of KinA. The authors also made use of an *in vivo* assay for two-component signal transduction based on the VanS/VanR system. The salicylanilides had antibacterial effects against Gram positive organisms but had no effect on wild type *E. coli*. However, a mutant *E. coli* strain possessing a leaky outer membrane was as sensitive to the compounds as any of the Gram positive organisms tested.

Hilliard *et al.* (1999) showed that both these families of compounds, tyramines and salicylanilides, have more mechanisms of action than just inhibition of two-component signal transduction systems. While the authors were able to show that RWJ-49815 inhibited the autophosphorylation of the HPK NRII, the compound also caused a rapid increase in the permeability of the membranes of *S. aureus* cells as determined by propidium iodide staining. Furthermore, the compounds triggered the rapid and complete lysis of equine erythrocytes. The salicylanilides caused little membrane damage and significantly less haemolysis, but there was no correlation between their inhibitory effects on the autophosphorylation of HPKs KinA and NRII and their antibacterial activity against Gram positives.

Fabret and Hoch (1998) identified a response regulator, YycF, in *Bacillus subtilis* that is required for this organism's growth. When a thermosensitive mutant of YycF is grown at a nonpermissive temperature, growth rapidly ceases and empty cells are formed that retain their structural integrity. YycF belongs to the OmpR winged helix-turn-helix family of DNA-binding proteins and has a paired histidine protein kinase, YycG. Both members of this two-component signal transduction system are transcribed throughout the growth phase of *B. subtilis* but are not transcribed in stationary phase.

Martin *et al.* (1999) identified a homologous two-component signal transduction system in *Staphylococcus aureus* that is also required for growth. The authors could not generate a YycF knock out, but, like Fabret and Hoch (1998), managed to generate a thermosensitive mutant strain with which they could determine that the YycG/YycF system is involved in controlling cell permeability.


Lange *et al.* (1999) have identified a YycG/YycF two-component signal transduction system in *Streptococcus pneumoniae* that is also required for

growth and there are YycG/YycF homologues in the genomes of at least two further Gram positives, *Enterococcus faecalis* and *Streptococcus pyrogenes*. The genome of *Lactococcus lactis* also possesses a *yycF* homologue but the genome does not appear to possess the pair histidine protein kinase YycG (Bolotin *et al.*, 1999). It is possible that these homologous and perhaps indispensable two-component signal transduction systems are one important target for the antibacterial compounds described above.

The diphenolic methanes, hydrophobic tyramines and substituted salicylanilides have inhibitory effects on the *in vivo* activity of two-component signal transduction systems and also have strong growth inhibitory activity against Gram positives while having little effect on Gram negatives with intact outer membranes (Domagala *et al.*, 1998; Barrett *et al.*, 1998; Macielag *et al.*, 1998).

## SUMMARY OF THE INVENTION

In a first aspect the present invention consists in a composition for use in inhibiting at least one phenotype of a microorganism, the composition comprising at least one compound of general formula I:



wherein  $R_1$  and  $R_2$  are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;


$R_3$  and  $R_4$  are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy, alkylsilyl;

$R_3$  or  $R_4 + R_2$  can be a saturated or an unsaturated cycloalkane;

and "-----" represents a single bond or a double bond provided that at least one of  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  is halogen and where  $R_3=H$  and  $R_4=Ph$ ,  $R_1$  and  $R_2$  can independently be H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or

arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

- 5 or a compound of general formula II




II

- 10 wherein R<sub>6</sub> and R<sub>7</sub> are independently H, halogen, carboxyl, ester, formyl, cyano, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic; X is a halogen;

- 15 R<sub>5</sub> is H, alkyl, alkenyl, alkynyl, alkene, alkyne, aryl, arylalkyl, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic.

- In a second aspect the present invention consists in a method of inhibiting at least one phenotype of a microorganism, the method comprising exposing the microorganism to a composition comprising at least one  
20 compound of general formula I:



I

- 25 wherein R<sub>1</sub> and R<sub>2</sub> are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

R<sub>3</sub> and R<sub>4</sub> are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy, alkylsilyl;


R<sub>3</sub> or R<sub>4</sub> + R<sub>2</sub> can be a saturated or an unsaturated cycloalkane;

and "-----" represents a single bond or a double bond provided that at least

- 5 one of R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> is halogen and where R<sub>3</sub>=H and R<sub>4</sub>=Ph, R<sub>1</sub> and R<sub>2</sub> can independently be H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

10

or a compound of general formula II



II

- 15 wherein R<sub>6</sub> and R<sub>7</sub> are independently H, halogen, carboxyl, ester, formyl, cyano, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic; X is a halogen;
- 20 R<sub>5</sub> is H, alkyl, alkenyl, alkynyl, alkene, alkyne, aryl, arylalkyl, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic.

The term "alkyl" is taken to mean both straight chain alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiary butyl, and the like. Preferably the alkyl group is a lower alkyl of 1 to 6 carbon atoms. The alkyl group may optionally be substituted by one or more groups selected from alkyl, cycloalkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkynyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, nitro, amino, nitroalkyl, nitroalkenyl, nitroalkynyl, nitroheterocyclyl, alkylamino, dialkylamino, alkenylamine, alkynylamino, acyl, alkenoyl, alkynoyl, acylamino, diacylamino, acyloxy, alkylsulfonyloxy, heterocyclyl, heterocycloxy, heterocyclamino, haloheterocyclyl,

30

alkylsulfenyl, alkylcarbonyloxy, alkylthio, acylthio, phosphorus-containing groups such as phosphono and phosphinyl.

The term "alkoxy" denotes straight chain or branched alkyloxy, preferably C<sub>1-10</sub> alkoxy. Examples include methoxy, ethoxy, n-propoxy, isopropoxy and the  
5 different butoxy isomers.

The term "alkenyl" denotes groups formed from straight chain, branched or mono- or polycyclic alkenes and polyene. Substituents include mono- or poly-unsaturated alkyl or cycloalkyl groups as previously defined, preferably C<sub>2-10</sub> alkenyl. Examples of alkenyl include vinyl, allyl, 1-methylvinyl, butenyl, iso-  
10 butenyl, 3-methyl-2-butenyl, 1-pentenyl, cyclopentenyl, 1-methyl-cyclopentenyl, 1-hexenyl, 3-hexenyl, cyclohexenyl, 1-heptenyl, 3-heptenyl, 1-octenyl, cyclooctenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 1-decenyl, 3-decenyl, 1,3-butadienyl, 1-4-pentadienyl, 1,3-cyclopentadienyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,3-cyclohexadienyl, 1,4-cyclohexadienyl, 1,3-cycloheptadienyl, 1,3,5-  
15 cycloheptatrienyl, or 1,3,5,7-cyclooctatetraenyl.

The term "halogen" denotes fluorine, chlorine, bromine or iodine, preferably bromine or fluorine.

The term "heteroatoms" denotes O, N or S.

The term "acyl" used either alone or in compound words such as  
20 "acyloxy", "acylthio", "acylamino" or diacylamino" denotes an aliphatic acyl group and an acyl group containing a heterocyclic ring which is referred to as heterocyclic acyl, preferably a C<sub>1-10</sub> alkanoyl. Examples of acyl include carbamoyl; straight chain or branched alkanoyl, such as formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl,  
25 hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl; alkoxycarbonyl, such as methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl or heptyloxycarbonyl; cycloalkanecarbonyl such as cyclopropanecarbonyl cyclobutanecarbonyl, cyclopentanecarbonyl or cyclohexanecarbonyl; alkanesulfonyl, such as methanesulfonyl or ethanesulfonyl; alkoxysulfonyl,  
30 such as methoxysulfonyl or ethoxysulfonyl; heterocycloalkanecarbonyl; heterocycloalkanoyl, such as pyrrolidinylacetyl, pyrrolidinylpropanoyl, pyrrolidinylbutanoyl, pyrrolidinylpentanoyl, pyrrolidinylhexanoyl or thiazolidinylacetyl; heterocyclylalkenoyl, such as heterocyclylpropenoyl, heterocyclylbutenoyl, heterocyclylpentenoyl or heterocyclylhexenoyl; or  
35 heterocyclyl glyoxyloyl, such as, thiazolidinylglyoxyloyl or pyrrolidinylglyoxyloyl.



As will be recognised by those skilled in the art the compounds of general formulas II, III and IV can exist as two isomers *e* and *z*. It is intended that the general formulas depicted herein are not limited to a particular isomer and encompass both isomers either in the form of a racemic mixture or  
5 separated isomers.

In a preferred embodiment the phenotype is controlled by a two-component signal transduction system. Preferably, the two-component signal transduction system is selected from, but not limited to, those whose response regulator belongs to the FixJ/LuxR subfamily or the OmpR  
10 subfamily of response regulators.

It is preferred that the phenotype of the microorganism is selected from the group consisting of growth, swarming/motility, biofilm formation,  
expression of virulence factors and combinations thereof.

In a preferred embodiment of the present invention the microorganism  
15 is selected from the group consisting of *Bacillus sp.*, *Streptococcus sp.*, *Helicobacter sp.*, *Mycobacterium sp.*, *Staphylococcus sp.*, *Enterobacter sp.*, *Pseudomonas sp.*, and *Bordatella sp.* In particular it is preferred that the microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus licheniformis*, *Streptococcus pneumoniae*, *Helicobacter pylori*, *Mycobacterium tuberculosis*, *Staphylococcus aureus*, *Staphylococcus epidermis*, *Enterobacter faecalis*, *Pseudomonas syringae*, *Pseudomonas aeruginosa*, and *Bordatella pertussis*.  
20

In a further preferred embodiment the composition comprises at least one compound selected from the group consisting of compounds 2, 3, 4, 30,  
25 33, 34, 80, 97 as set out in Table 1 and combinations thereof.

In a third aspect the present invention consists in a method of preventing or reducing biofilm formation on a surface, the method comprising applying to the surface the composition of the first aspect of the present invention.

30 In a fourth aspect the present invention consists in a method of treating bacterial infection or decreasing the severity of symptoms of bacterial infection in an animal, the method comprising administering to the animal an effective amount of the composition of the first aspect of the present invention.

35 The composition of the present invention can be used in environmental, sanitary, veterinary, or medical applications where it is

possible to effect the phenotype of a microorganism, particularly through inhibition of a two-component signal transduction system. A particular two-component signal transduction system maybe targeted by use or selection of the compound or mixture of compounds. Similarly, a particular  
5 microorganism may be targeted by use or selection of the compound or mixture of compounds.

Applications include, but are not limited to, inhibition of growth of microbial pathogens in environmental situations, reduction or prevention of microbial colonisation of medical media including washing solutions,  
10 ointments and the like, inhibition of microbial attachment to surfaces and subsequent biofilm formation, as active ingredients in antiseptics and disinfectants.

As will be recognised by those skilled in the art the compounds of formulae I and II can be usefully incorporated in a varied range of  
15 compositions. For example the compounds can be incorporated in a range of personal care products such as deodorants, soaps, shampoos, dentifrices etc. The manufacture of such compositions is well known in the art and the compounds of formulae I and II or mixtures thereof can be simply included in these compositions in admixture.

20 The ability of compositions comprising the compounds of formulae I and II or mixtures to inhibit phenotypes of a range of bacteria provides a number of useful applications of these compositions. In particular the compositions may be formulated for pharmaceutical use with human and non-human animals. In one embodiment of the invention the compositions  
25 are formulated for topical application for use, for example, in application to wounds and the like. In this regard they may be directly incorporated into bandages and the like.

The compositions of the present invention will also find application in preventing or inhibiting biofilm formation. In another embodiment the  
30 compositions will find application as washing solutions, particularly in contact lens cleaning compositions.

It has been found by the present inventors that with a number of the compounds a concentration of less than 25µg/ml *in vivo* is sufficient to inhibit the normal function of a number of two-component signal  
35 transduction systems. It will be appreciated, however, that the concentration required may depend on a number of factors including the microorganism,

the furanone compound(s) used, the two-component signal transduction system to be inhibited, and the formulation of the furanone into the product.

Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a  
5 stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

#### DETAILED DESCRIPTION

10 In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following non-limiting examples and drawings.

---

#### FIGURE LEGEND

15

Figure 1 shows the growth responses of *Bacillus subtilis* strain ATCC 6633 and NCTC 10073 to compound 2. The compound was added at 8-9 hours, as denoted by the arrows, after the cultures had been growing. *B. subtilis* has a two component system that, when deleted, results in lysis and  
20 cell death. Addition of the compounds to *B. subtilis* also results in the induction of cell lysis, which can be observed as a cessation of growth and even a decrease in optical density. Therefore, this data suggests that the compounds interfere with this two component system and cause cell death or prevent growth.

25

#### Bacterial Strains and Plasmids

The bacterial strains and plasmids used in the following Examples are set out in Table 2.

#### 30 Two-Component signal transduction Assays

##### *Taz-1 Assay*

The Taz-assay carried out according to the method of Jin and Inouye (1993) with the following alterations. *E. coli* RU1012 (pYT0301) were grown overnight in M9 medium at 37°C supplemented with 100µg/ml ampicillin and  
35 50µg/ml kanamycin. This overnight culture was then used to inoculate 50ml M9 medium in side-arm flasks which were then incubated at 37°C and

shaken at 180 rpm. The  $OD_{610}$  of the growing cultures was monitored regularly and when the  $OD_{610} = 0.2$  the cultures were placed on ice. Aspartate was added to side-arm flasks to give a final concentration of 3mM (aspartate stock solution made up in M9 salts).

5        The test compound or mixtures of compounds were dissolved in ethanol and added to cultures to give the required final concentrations. Negative controls were prepared with equal volumes of ethanol. Cultures were then placed in a 37°C incubator and shaken for 4 hours ( $OD_{610}$  approximately 0.7) before being removed and put on ice. Samples were then  
10 removed for  $\beta$ -galactosidase assays carried out according to the method of Miller (1972).

The results obtained in this assay are set out in Table 3.

#### *CopS/CopR Assay*

15        *P. syringae* pv *syringae* PS61 (pCOP38)(pPT23D) was grown on SWM media (Kinscherf and Willis, 1999) at room temperature with shaking for 48 hours. Five  $\mu$ g/ml streptomycin, 15 $\mu$ g/ml chloramphenicol and 1.0mM  $CuSO_4$  were added to maintain plasmids. This culture was used to inoculate 50ml SWM media in side-arm flasks with the addition of antibiotics. These  
20 cultures were incubated at room temperature with shaking for 16 hours ( $OD_{610} = 0.2$ ) at which point  $CuSO_4$  was added to a concentration of 0.075mM ( $CuSO_4$  solution made up in MQ water).

The test compound or mixtures of compounds were dissolved in ethanol and added to cultures to give the required final concentrations.  
25 Equal volumes of ethanol were added to  $Cu^{2+}$  negative and positive cultures. Cultures were incubated for 6.5 hours at room temperature with shaking before being placed on ice. Samples were then removed for  $\beta$ -galactosidase assays.  $\beta$ -galactosidase assays were carried out in the same manner as those for the Taz assay described above.

30        The effect of furanone compound 3 on the CopS/CopR two component signal transduction system that regulates copper resistance in *Pseudomonas syringae* pv. *syringae* (Mills *et al.*, 1993) was assessed. Compound 3 at concentrations of 25 $\mu$ g/ml and 50 $\mu$ g/ml significantly reduced *cop'-lacZ* expression ( $p > 0.05$ ). However, there appears to be no difference in terms of  
35 *lacZ* expression between the two concentrations ( $p > 0.15$ ). Compound 3 did not have any growth inhibitory effects at the concentrations used.

Compound 4 also appeared to reduce the normal activity of the CopS/CopR two-component signal transduction system.

#### *GacS/GacA Assay*

5        *P. syringae* var tomato BB27 was grown overnight in SWM media at room temperature. This culture was used to stab inoculate SWM plates made up with 0.4% agar and incubated at room temperature (20°C). The culture was also used to stab inoculate sets of SWM plates (0.4% agar) that had been made up with 25µg/ml and 50µg/ml of the test compound (stock solutions  
10        made up in ethanol). These plates were also incubated at room temperature for 36 hours before being examined for swarming activity and photographed. Before use all 0.4% agar SWM plates were allowed to air-dry for two hours in a laminar flow cabinet at room temperature.

15        Furanones interfere with the "swarming" response of *Pseudomonas syringae*, which is regulated by the GacS/GacA two-component signal transduction system (Kinscherf and Willis, 1999). Furanone compound 3 was found to shut down swarming at 50µg/ml and dramatically alters the swarming pattern at a concentration of 25µg/ml. Compound 3 did not inhibit the growth of *P. syringae* var. tomato at a concentration of 50µg/ml.  
20        Furanone compound 30 also inhibited the swarming response in *P. syringae*.

#### Growth curves

25        Growth curve method. Bacteria are grown overnight in standard medium. The following morning, the cells were inoculated into fresh medium at 1% (a 1 in 100 dilution). Furanones were added either at the beginning of growth (time 0) or, as was the case for the *B. subtilis* experiments, the results of which are shown in Figure 1, during the mid-logarithmic phase of growth. Growth was then monitored regularly by spectrophotometric readings, at a wavelength of 610 nm.

#### MIC's for *Staphylococcus aureus*

30        Using the type of growth described above, the minimum growth inhibitory concentration of furanones was determined for *S. aureus* and *Streptococcus* spp. were determined for a range of compounds. The results  
35        are set out in Table 4.

Without wishing to be bound by scientific theory it would appear from the data presented above that the compounds and mixtures thereof interfere with the normal function of a number of two-component signal transduction systems:

- 5       - the compounds shut down signal transduction triggered by aspartate in the Taz-assay;
- reduce the degree of signal transduction triggered by  $\text{Cu}^{2+}$  ions in the CopS/CopR assay; and
- appear to modulate swarming in *P. syringae* that is known to be, at least in part, regulated by the GacS/GacA two-component signal transduction system.

#### Furanones as Inhibitors of Signal Transduction Systems: Effects on the Colonisation of Surfaces

15       Given that the furanones and related compounds of the present invention interfere with the normal function of two-component signal transduction systems, it may be that the furanones block the attachment of bacteria to the surface, by interfering with one or more of these systems.






      There is certainly some evidence that two-component signal transduction systems play a central role in the attachment of bacteria to surfaces. For example, the ColS/ColR two-component signal transduction system in *Pseudomonas fluorescens* strain WCS365 plays an important role in the attachment of this bacterial strain to root surfaces (Dekkers *et al.*, 1998). A mutant strain with a *colS/colR* deletion colonises root surfaces up to 1,000 fold less efficiently than a wild-type strain. This reduced ability to attach to a surface could not be ascribed to any defects in chemotaxis, motility or a reduced ability to take up a range of plant exudates. No gene or set of genes has yet been found that is regulated by this two-component signal transduction system, nor do the identities of ColR and ColS's closest characterised homologues, which include CopR<sub>*P. syringae*</sub> (61% similarity and 38.5% identity) in the case of ColR and CpxA<sub>*E. coli*</sub> (53% similarity and 26% identity) in the case of ColS, indicate what phenotype(s) this two-component system regulate.

      Recently Philippe Lejeune and colleagues have shown that two-component signal transduction systems play an important role in the attachment of *E. coli* to abiotic surfaces. Firstly, it was demonstrated that the






EnvZ/OmpR two-component system was important for attachment and subsequent biofilm formation (Vidal *et al.*, 1998). It was shown that OmpR controls the production of the curli by directly regulating the expression of *csgA*, which encodes one of the major components of curli. Curli appear to be absolutely required for attachment and biofilm formation by *E. coli* for both characterised laboratory strains and a limited number of clinical isolates (Vidal *et al.*, 1998; Dorel *et al.*, 1999). Secondly, the CpxA/CpxR two-component system similarly regulates the expression of the *csgA*, thereby controlling the number of curli produced (Dorel *et al.*, 1999). Other groups have demonstrated that structures on the surface of *E. coli* are important for attachment, for example Pratt and Kolter (1998) demonstrated that type I pili are required for *E. coli* strains to permanently attach to a surface, and it is likely that two-component signal transduction systems play some role in their regulation.

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

Table 1

Compound No.	Structure
2 (d3)	
3 (d5)	
4 (d19)	
30	
33	



Compound No.	Structure
34	 <chem>BrC1(Br)C(CCC)C(=O)O1</chem>
75	 <chem>CC1C(C)C(=O)O1</chem>
76	 <chem>CC1C(C)C(=O)O1</chem>
80	 <chem>CC1C(Br)C(=O)O1</chem>
92	 <chem>BrC1(Br)C(CCC)C(=O)O1</chem>




Compound No.	Structure
96	 <chem>CCCCC1=C(C(=O)OCC)C(=O)C=C1C=C</chem>
97	 <chem>C=C(C)C1=C(Br)C(=O)C=C1O</chem>
AI9	 <chem>C=C(C)[Si](C)(C)C1=C(C)C(=O)C=C1O</chem>

Table 2

Strain	Genotype	Reference
<i>Escherichia coli</i> RU1012	$\emptyset(ompC-lacZ)10-25$ , $\Delta envZ::Km^R$	Utsumi <i>et al.</i> , 1989
<i>E. coli</i> RC11/ $\lambda$ LK1	$\Delta narXL$ , $\Delta narQ::Km^R$ , $recA56$ , $\lambda PC51 \emptyset(narG-lacZ)$	Cavicchioli <i>et al.</i> , 1995
<i>P. syringae</i> pv. <i>syringae</i> PS61	Rif <sup>S</sup> , Cam <sup>R</sup> , Cu <sup>S</sup>	Bender & Cooksey, 1986
<i>P. syringae</i> var. <i>tomato</i> BB27	wild-type	UNSW Culture Collection
Plasmids	Description	Reference
pYT0301	<i>tar-envZ</i> (Taz-1), Amp <sup>R</sup>	Yang & Inouye, 1991
pLK63	<i>narX</i> <sup>+</sup> , <i>narL</i> <sup>+</sup> , Cm <sup>R</sup>	Kalman & Gunsalus, 1989
pCOP38	Sm <sup>R</sup> , Cm <sup>R</sup> , pMP190 with <i>cop-lacZ</i> promoter fusion	Mellano & Cooksey, 1988
pPT23D	Cu <sup>R</sup> , wild-type plasmid carrying <i>cop</i> operon and <i>copSicopR</i>	Bender & Cooksey, 1986

Table 3

<i>Treatment</i>	<i>Percentage Induction</i>
C2 15 µg/ml	34.6
C2 25 µg/ml	15.0
Negative Control	23.7

<i>Treatment</i>	<i>Percentage Induction</i>
C3 25 µg/ml	27.0
Negative Control	25.5

5

<i>Treatment</i>	<i>Percentage Induction</i>
C30 5.0 µg/ml	36.9
C34 2.5 µg/ml	76.1
Negative Control	17.2

<i>Treatment</i>	<i>Percentage Induction</i>
C30 1.25 µg/ml	52.3
C30 2.50 µg/ml	34.5
C34 1.25 µg/ml	92.8
C34 2.50 µg/ml	64.0
Negative Control	8.5

10

<i>Treatment</i>	<i>Percentage Induction</i>
C75 25 µg/ml	122.6
C76 25 µg/ml	111.2
Negative Control	5.6

Table 3 (cont)

<i>Treatment</i>	<i>Percentage Induction</i>
C80 25 µg/ml	71.6
AI9 0.5 µg/ml	113.4
AI9 1.0 µg/ml	94.2
Negative Control	17.8

Table 4. Minimum inhibitory (growth) concentrations of furanones

Compound	<i>Staphylococcus aureus</i>	<i>Streptococcus spp.</i>
2	1 -10 ug/ml	Not Tested
3	Not tested	Not tested
4	Not Tested	10 ug/ml
30	1-20 ug/ml	10 ug/ml
33	500 ng/ml	Not tested
34	250 ng/ml	Not tested
33/34	1 ug/ml	10 ug/ml
45	1-20 ug/ml	10 ug/ml
80	Not Tested	Not tested
97	Not Tested	Not tested

## REFERENCES

- Arthur, M., C Molinas, and P Courvalin 1992. The VanS-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in *Enterococcus faecium* BM4147. *J. Bacteriol.* 174: 2582-2591
- Barrett, J. F., R. M. Goldschmidt, L. E. Lawrence, B. Foleno, R. Chen, J. P. Demers, S. Johnson, R. Kanojia, J. Fernandez, J. Bernstein, L. Licata, A. Donetz, S. Huang, D. J. Hlasta, M. J. Macielag, K. Ohemeng, R. Frechette, M. B. Frosco, D. H. Klaubert, J.M. Whiteley, L. Wang, and J. A. Hoch 1998. Antibacterial agents that inhibit two-component signal transduction systems. *Proc. Natl. Acad. Sci. USA* 95: 5317-5322
- Bender, C. L., and D. A. Cooksey 1986. Indigenous plasmids in *Pseudomonas syringae* pv. tomato: conjugative transfer and role in copper resistance. *J. Bacteriol.* 165: 534-541
- Bolotin, A., S. Mauger, K. Malarne, S. D. Ehrlich and A. Sorokin 1999. Low-redundancy sequencing of the entire *Lactococcus lactis* IL1403 genome. *Antonie van Leeuwenhoek* 76: 27-76
- Cavicchioli, R., I Schroder, M Constanti, and RP Gunsalus 1995. The NarX and NarQ sensor-transmitter proteins of *Escherichia coli* each require two conserved histidines for nitrate-dependent signal transduction to NarL. *J. Bacteriol.* 177: 2416-2424
- Dekkers, L. C., C. J. P. Bloemendaal, L. A. de Weger, C. A. Wijffelman, H. P. Spaink and B. J. J. Lugtenberg 1998. A two-component system plays an important role in the root-colonizing ability of *Pseudomonas fluorescens* strain WCS365. *Molecular Plant-Microbe Interactions* 11(1): 45-56
- Deretic, V., R. Kishit, W. M. Konyesni, A. M. Chakrabarty and T. K. Misra 1989. The *algR* gene, which regulates mucoidy in *Pseudomonas aeruginosa*, belongs to a class of environmentally responsive genes. *J. Bacteriol.* 171: 1278-1283

- Dorel, C., O. Vidal, C. Prigent-Combaret, I. Vallet and P. Lejeune 1999. Involvement of the Cpx signal transduction pathway in *E. coli* in biofilm formation. *FEMS Microbiology Letters* 178: 169-175
- 5 Fabret, C., and J. A. Hoch 1998. A two-component signal transduction system essential for growth of *Bacillus subtilis*: implications for anti-infective therapy. *J. Bacteriol.* 180: 6375-6383
- Hilliard, J. J., R. M. Goldschmidt, L. Licata, E. Z. Baum, and K. Bush 1999.
- 10 Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems. *Antimicrobial Agents and Chemotherapy* 43: 1693-1699
- Jin, T., and M. Inouye. 1993. Ligand binding to the receptor domain
- 15 regulates the ratio of kinase to phosphatase activities of the signalling domain of the hybrid *Escherichia coli* transmembrane receptor, Taz1. *J. Mol. Biol.* 232: 484-492
- Kalman, L. V., and R. P. Gunsalus 1989. Identification of a second gene
- 20 involved in global regulation of fumarate reductase and other nitrate-controlled genes for anaerobic respiration in *Escherichia coli*. *J. Bacteriol.* 171: 3810-3816
- Kinscherf, T. G., and D. K. Willis 1999. Swarming by *Pseudomonas syringae*
- 25 B728a requires *gacS* (*lemA*) and *gacA* but not the acyl-homoserine lactone biosynthetic gene *ahlI*. *J. Bacteriol.* 181: 4133-4136
- Lange, R., C. Wagner, A. de Saizieu, N. Flint, J. Molnos, M. Stieger, P. Caspers, M. Kamber, W. Keck and K. E. Amrein 1999. Domain organisation
- 30 and molecular characterization of 13 two-component systems identified by genome sequencing of *Streptococcus pneumoniae*. *Gene* 237: 223-234
- Macielag, M. J., J. P. Demers, S. A. Fraga-Spano, D. J. Hlasta, S. G. Johnson, R. M. Kanojia, R. K. Russell, Z. Sui, M. A. Weidner-Wells, H. Werblood, B. D.
- 35 Foleno, R. M. Goldschmidt, M. J. Loeloff, G. C. Webb, and J. F. Barrett 1998.



Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. *J. Med. Chem.* 41: 2939-2945

- 5 Martin, P. K., T. Li, D. Sun, D. P. Biek, and M. B. Schmid 1999. Role in cell permeability of an essential two-component system in *Staphylococcus aureus*. *J. Bacteriol.* 181: 3666-3673

- 10 Mellano, M. A., and D. A. Cooksey 1988. Induction of the copper resistance operon from *Pseudomonas syringae* pv. tomato. *J. Bacteriol.* 170: 4399-4401

Mills, S. D., C. A. Jasalavich and D. A. Cooksey 1993. A two-component system required for copper-inducible expression of the copper resistance operon of *Pseudomonas syringae*. *J. Bacteriol.* 175: 1656-1664

- 15 Pratt, L. A., and R. Kolter 1998. Genetic analysis of *Escherichia coli* biofilm formation: roles of flagella, motility, chemotaxis and type I pili. *Mol. Microbiol.* 30: 285-293

- 20 Roychoudhury, S., N. A. Zielinski, A. J. Ninfa, N. E. Allen, L. N. Jungheim, T. I. Nicas, and A. M. Chakrabarty. 1993. Inhibitors of two-component signal transduction systems: inhibition of alginate gene activation in *Pseudomonas aeruginosa*. *Proc. Natl. Acad. Sci. USA* 90: 965-969

- 25 Uljasz, A. T., and B. Weisblum 1999. Dissecting the VanRS signal transduction pathway with specific inhibitors. *J. Bacteriol.* 181: 627-631

- 30 Utsumi, R., R. E. Brisette, A. Rampersaud, S. A. Forst, K. Oosawa and M. Inouye 1989. Activation of bacterial porin gene expression by a chimeric signal transducer in response to aspartate. *Science* 245: 1246-1249


- 35 Vidal, O., R. Longin, C. Prigent-Combaret, C. Dorel, M. Hooreman and P. Lejeune 1998. Isolation of an *Escherichia coli* K-12 mutant strain able to form biofilms on inert surfaces: involvement of a new *ompR* allele that increases curli expression. *J. Bacteriol.* 180(9): 2442-2449

Yang, Y., and M. Inouye 1991. Intermolecular complementation between two defective mutant signal transducing receptors of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* 88: 11057-11061

## CLAIMS:-


1. A composition for use in inhibiting at least one phenotype of a microorganism, the composition comprising at least one compound of general formula I:

5



- wherein  $R_1$  and  $R_2$  are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;
- $R_3$  and  $R_4$  are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy, alkylsilyl;
- $R_3$  or  $R_4 + R_2$  can be a saturated or an unsaturated cycloalkane; and "-----" represents a single bond or a double bond provided that at least one of  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  is halogen and where  $R_3=H$  and  $R_4=Ph$ ,  $R_1$  and  $R_2$  can independently be H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

or a compound of general formula II



25

wherein  $R_6$  and  $R_7$  are independently H, halogen, carboxyl, ester, formyl, cyano, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether

unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic; X is a halogen;

R<sub>5</sub> is H, alkyl, alkenyl, alkynyl, alkene, alkyne, aryl, arylalkyl, whether

- 5 unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic.

2. A composition as claimed in claim 1 in which the phenotype is controlled by a two-component signal transduction system.

3. A composition as claimed in claim 1 or claim 2 in which the  
10 phenotype of the microorganism is selected from the group consisting of growth, swarming/motility, expression of virulence factors and combinations thereof.

4. A composition as claimed in any one of claims 1 to 3 in which the microorganism is selected from the group consisting of *Bacillus sp.*,  
15 *Streptococcus sp.*, *Helicobacter sp.*, *Mycobacterium sp.*, *Staphylococcus sp.*, *Enterobacter sp.*, *Pseudomonas sp.*, and *Bordatella sp.*

5. A composition as claimed in claim 4 in which the microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus licheniformis*, *Streptococcus pneumonia*,  
20 *Helicobacter pylori*, *Mycobacterium tuberculosis*, *Staphylococcus aureus*, *Staphylococcus epidermis*, *Enterobacter faecalis*, *Pseudomonas syringae*, *Pseudomonas aeruginosa*, and *Bordatella pertusis*.

6. A composition as claimed in any one of claims 1 to 5 in which the composition comprises a pharmaceutically acceptable carrier or excipient.

- 25 7. A composition as claimed in any one of claims 1 to 5 in which the composition is a dentifrice.

8. A composition as claimed in any one of claims 1 to 5 in which the composition is a deodorant.


9. A composition as claimed in any one of claims 1 to 5 in which the  
30 composition is a cleaning composition.

10. A composition as claimed in any one of claims 1 to 5 in which the composition is a hair cleaning composition.




11. A composition as claimed in any one of claims 1 to 5 in which the composition is a contact lens cleaning composition.

- 35 12. A composition as claimed in any one of claims 1 to 5 in which the composition is a soap.

13. A composition as claimed in claim 6 in which the composition is formulated for topical administration.
14. A composition as claimed in claim 6 in which the composition is applied to a bandage.
- 5 15. A composition as claimed in any one claims 1 to 14 in which the composition comprises at least one compound selected from the group consisting




10



15


29



5 and combinations thereof.

16. A method of inhibiting at least one phenotype of a microorganism, the method comprising exposing the microorganism to a composition comprising at least one compound of general formula I:

10



wherein  $R_1$  and  $R_2$  are independently H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;


5  $R_3$  and  $R_4$  are independently H, halogen, alkyl, aryl or arylalkyl, alkoxy, alkylsilyl;

$R_3$  or  $R_4 + R_2$  can be a saturated or an unsaturated cycloalkane;

and "-----" represents a single bond or a double bond provided that at least one of  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  is halogen and where  $R_3=H$  and  $R_4=Ph$ ,  $R_1$  and  $R_2$

10 can independently be H, halogen, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic;

15 or a compound of general formula II





wherein  $R_6$  and  $R_7$  are independently H, halogen, carboxyl, ester, formyl, cyano, alkyl, alkoxy, oxoalkyl, alkenyl, aryl or arylalkyl whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic; X is a halogen;

20  $R_5$  is H, alkyl, alkenyl, alkynyl, alkene, alkyne, aryl, arylalkyl, whether unsubstituted or substituted, optionally interrupted by one or more heteroatoms, straight chain or branched chain, hydrophilic or fluorophilic.

17. A method as claimed in claim 16 in which the phenotype is controlled by a two-component signal transduction system.





18. A method as claimed in claim 16 or claim 17 in which the phenotype of the microorganism is selected from the group consisting of growth, swarming/motility, expression of virulence factors and combinations thereof.

19. A method as claimed in any one of claims 16 to 18 in which the microorganism is selected from the group consisting of *Bacillus sp.*, *Streptococcus sp.*, *Helicobacter sp.*, *Mycobacterium sp.*, *Staphylococcus sp.*, *Enterobacter sp.*, *Pseudomonas sp.*, and *Bordatella sp.*
- 5 20. A method as claimed in claim 19 in which the microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus anthracis*, *Bacillus cereus*, *Bacillus licheniformis*, *Streptococcus pneumonia*, *Helicobacter pylori*, *Mycobacterium tuberculosis*, *Staphylococcus aureus*, *Staphylococcus epidermis*, *Enterobacter faecalis*, *Pseudomonas syringae*,
- 10 *Pseudomonas aeruginosa*, and *Bordatella pertusis*.
21. A method as claimed in any one of claims 16 to 20 in which the composition comprises a pharmaceutically acceptable carrier or excipient.
22. A method as claimed in any one of claims 16 to 20 in which the composition is a dentifrice.
- 15 23. A method as claimed in any one of claims 16 to 20 in which the composition is a cleaning composition.
24. A method as claimed in any one claims 16 to 23 in which the composition comprises at least one compound selected from the group consisting of
- 20







32



5




and combinations thereof.

25. A method of preventing or reducing biofilm formation on a surface, the method comprising applying to the surface a composition as claimed in any one of claims 1 to 15.
26. A method of treating bacterial infection or decreasing the severity of
- 5 symptoms of bacterial infection in an animal, the method comprising administering to the animal an effective amount of the composition as claimed in claim 6.

1/1

Figure 1:

**Growth responses of *Bacillus subtilis* strains ATCC 6633 and NCTC 10073 to furanone compound 2 (25 µg/ml)**



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/AU 00/01553

## A. CLASSIFICATION OF SUBJECT MATTER

Int Cl<sup>7</sup>: A61K 31/341, 31/121, 7/16, 7/32, 7/06, A61P 31/04, A61L 12/10, C11D 9/50

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
STN (File CA) Chemical Structure and Keywords: microorg., bacter., antibacter., phenotyp.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Tetrahedron Letters No. 22, 1977, McConnell et al., "Polyhalogenated.... Asparagoides", pages 1851-54. See whole document, in particular compounds 1 to 5 page 1851	1-26
X	Biofouling, Vol. 8(4), 1995, De Nys et al., "Broad spectrum... assays, pages 259-71. See abstract and fig. 1 page 261	1-26
X	Pro. Int. Seaweed Symp., Vol. date 1997,9, Issue date 1979, Fenical et al. "Antibiotics and... (florideophyceae)" See abstract and pages 389-391	1-26

☒ Further documents are listed in the continuation of Box C

☒ See patent family annex

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" Document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
19 February 2000

Date of mailing of the international search report

21 February 2001

Name and mailing address of the ISA/AU  
AUSTRALIAN PATENT OFFICE  
PO BOX 200  
WODEN ACT 2606 AUSTRALIA  
E-mail address: pct@ipaustalia.gov.au  
Facsimile No.: (02) 6285 3929

Authorized officer

J.G. HANSON

Telephone No.: (02) 6283 2262

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 00/01553

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Microbiology (Reading U.K.), Vol. 145(2), 1999. Manefield et al., "Evidence that... protein", pages 283-91 See abstract, in particular the last sentence and fig 1 page 285	1-26
X	J. Bacteriol., Vol. 180(2), 1998, Kjelleberg et al., "Extracellular... strain S14", pages 201-09 See abstract, fig 1 page 202 and page 207 column 1, paragraph commencing with "Furanones..."	1-26
X	EP 0067124 A( CIBA-GEIGY AG) 2 May 1985 See claims 1, 9	1-26
X	AU 49996/96 (708962) B UNISEARCH LTD.) 26 September 1996 See page 2 lines 12-22, page 4 lines 1-7, page 12 table 2 and figs. 1-3	1-26
X	WO 99/53915 A (UNISEARCH LTD.) 28 October 1999 See the document as a whole	1-26
X	WO 99/54323 A (UNISEARCH LTD.) 28 October 1999 See claims 1, 22 and 24	1-26

### Information on patent family members

**PCT/AU 00/01553**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
EP	0067124	IL	65964	JP	58023642		
AU	49996/96	WO	96/26392	BR	9607661	EP	815201
		CA	2215797	CN	1185173		
WO	99/53915	AU	33224/99	EP	1071416		
WO	99/54323	AU	33225/99	EP	1071677		